NHS Breakthrough: New Genetic Testing to Transform Cancer Care for Ethnic Minority Patients
The latest NHS health news has revealed a breakthrough in cancer treatment in the UK, as the NHS rolls out enhanced genetic testing designed to improve safety and outcomes for patients from minority ethnic backgrounds.
For the first time, thousands of patients across England will benefit from advanced pre-chemotherapy genetic testing that better identifies risks linked to severe side effects. Experts are calling the move “groundbreaking”, marking a significant step forward in tackling long-standing health inequalities in cancer care.
Chemotherapy remains one of the most widely used treatments for cancer, but it can come with serious side effects, including nausea, fatigue, hair loss and, in some cases, life-threatening complications. In England alone, around 38,000 patients receive fluoropyrimidine-based chemotherapy each year, with up to 40% experiencing adverse drug reactions. This makes accurate testing before treatment crucial.
Until recently, NHS genetic screening focused on four variants of the DPYD gene—variants primarily found in people of white European descent. This meant the tests were less effective for patients from Black and other minority ethnic backgrounds, who were at greater risk of severe reactions because key genetic markers were not being detected.
Now, the NHS has introduced testing for a fifth DPYD gene variant, which is more commonly found in Black and minority ethnic populations. This vital update ensures that chemotherapy can be more accurately tailored to individual patients, reducing the risk of harmful side effects and potentially saving lives.
Healthcare leaders say the change represents a turning point in personalised medicine within the NHS. By expanding the scope of genetic testing, clinicians can now make more informed decisions about chemotherapy dosages, ensuring safer and more effective treatment plans for a broader range of patients.
Early results are already promising. Since the updated testing was introduced at Manchester University NHS Foundation Trust, patients from minority backgrounds have received adjusted chemotherapy doses based on their genetic profiles—significantly lowering their risk of dangerous reactions.
Experts have long warned that ethnic disparities in healthcare are driven in part by a lack of diversity in medical research. Historically, much of the research behind drug safety and genetic testing has been conducted on white populations, leaving gaps in understanding how treatments affect other groups.
This latest development signals a shift towards more inclusive healthcare. Leaders within the NHS emphasise that this is not just a scientific advancement, but a meaningful step towards ensuring equal access to safe and effective treatment for all patients, regardless of ethnicity.
The move also highlights the growing importance of genomics and precision medicine, which aim to tailor treatments to individual genetic profiles. As research becomes more inclusive, the potential for more effective, targeted therapies continues to grow.
Ultimately, this new genetic testing programme reinforces the NHS’s commitment to delivering fairer, safer cancer care in the UK, ensuring no patient is placed at unnecessary risk due to gaps in medical understanding.
